Attached files
file | filename |
---|---|
8-K - CURRENT REPORT - CBA Florida, Inc. | cbai_8k.htm |
Exhibit 99.9
Cord Blood America, Inc. Announces Resignation of Interim
President
July 11, 2017 - Cord Blood America, Inc.
(www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or
the "Company") today announced that Stephen Morgan will resign from
his positions as Interim President, General Counsel, and Corporate
Secretary effective July 19, 2017, in order to pursue other career
opportunities in his home state of Minnesota where he can devote
more time to his family. Mr. Morgan will be available to assist
with the transition and consult with the Company on an as needed
basis. Effective July 19, 2017, the Company’s board of
directors has named director and chairman of the audit committee
Anthony Snow as Interim President.
Commenting on Mr. Morgan’s resignation, David Sandberg,
Chairman of Cord Blood America, Inc. stated, “On behalf of
our board of directors and our employees, I would like to thank
Steve for his commitment and contributions to the Company. We
wish him much success in his future endeavors.”
Mr. Morgan said, “For family and personal reasons I have made
the very difficult decision to resign from my position with CBAI. I
would like to thank the Board for giving me the opportunity to lead
the Company and remain confident that the team will continue to
execute on our strategy and the Company will enjoy great
success.”
About Cord Blood America, Inc.
Cord Blood America, Inc. is the parent company of CorCell
Companies, Inc. which, along with Cord Blood America, Inc.,
facilitates umbilical cord blood and cord tissue stem cell
processing and storage for expectant parents and their children.
Collected through a safe and non-invasive process, cord blood stem
cells offer a powerful and potentially life- saving resource for
treating a growing number of ailments, including cancer, leukemia,
blood, and immune disorders. To find out more about Cord Blood America, Inc. and CorCell
Companies, Inc., visit our websites: http://www.cordblood-america.com/ for investor
information and http://www.corcell.com/ for
customer information.
Forward-Looking Statements
Some statements made in this press release are forward-looking
statements. We use words such as "anticipate," "believe,"
"expect,'' "future," "intend," "plan," and similar expressions to
identify forward-looking statements. These statements including
those related to the growth of the industry, new stem cell
treatments, and Cord Blood America's performance, are only
predictions and are subject to certain risks, uncertainties and
assumptions. Additional risks are identified and described in the
Company's public filings with the Securities and Exchange
Commission. Statements made herein are as of the date of this press
release and should not be relied upon as of any subsequent date.
The Company's past performance is not necessarily indicative of its
future performance. The Company does not undertake, and the Company
specifically disclaims any obligation to update any forward-looking
statements to reflect occurrences, developments, events, or
circumstances after the date of such statement.
Investor Contact: investor@cordblood-america.com
SOURCE: Cord Blood
America, Inc.